Washington Analysis
August 13, 2008
Page 3 of 7
McCain Obama
Healthcare:
Medicare &MedicareAdvantage
(MA)
Unlikely to support MA changes. Has calledMedicare a “fiscal train wreck.” Supportsindexing Part D premiums.Positive for Medicare Advantage plans[
Humana
(HUM-$50),
Coventry
(CVH-$38),
WellCare
(WCG-$42),
UniversalAmerican
(UAM-$13),
HealthNet
(HNT-$28). But negative for
hospitals, nursinghomes, home health agencies
,
oxygensuppliers
, and other providers, which wouldbe at risk for smaller reimbursementincreases or freezes.Supports cutting Medicare Advantage planpayments to parity with fee-for-serviceamounts.Negative for
Medicare Advantage
names.Less risk of smaller increases or freezes for
hospitals, nursing homes, home healthagencies, oxygen suppliers
and other
providers
.
Healthcare:
DirectNegotiation of Medicare Part DDrug Prices
In the past, supported allowing directnegotiation, but not requiring it. He has nottalked about it as part of healthcare platform.Negative risk for
pharma
and
biotechmakers
and
pharmacy benefit managers(PBMs)
. Much depends on bill and CMSregs. Also puts long-term pressure on drugpricing in commercial insurance space.Potentially positive for
generics
due togreater volumes despite lower rates.Supports direct negotiation of Medicare drugbenefit prices but doesn’t requiring it.Negative risk for
pharma
and
biotech makers
and
pharmacy benefit managers (PBMs)
.Much depends on bill and CMS regs. Also putslong-term pressure on drug pricing incommercial insurance space. Potentiallypositive for
generics
due to greater volumesdespite lower reimbursements.
Healthcare:
Drug Reimports
Supports reimportation
if
drugs are safe andprices lower outside U.S.Supports reimportation
if
drugs are safe andprices lower outside U.S.
Healthcare:
Follow-onBiologics(FOBs)
Supports faster introduction of generics andbiologics. Positive for
Teva
(TEVA-$46),
Novartis
(NVS-$57),
Barr
(BRL-$67), and
Momenta
(MNTA-$17),
which woulddevelop FOBs; however, we suspect that hewould push for biotech to get long marketingexclusivity periods.Supports pathway for FOBs, which would be apositive for
Teva
,
Novartis
,
Barr
, and
Momenta
. Separately, supports the use of generics and prohibits tactics (reverse patentdrug settlements) to prevent generics fromcoming to market. Mixed for
generics
andnegative for
brand-name pharma.
Energy:
Climate Change
Supports a 60% reduction in greenhouse gas(GHG) emissions by 2050 through a cap andtrade mechanism. The plan also calls for theU.S. to reduce GHG emissions to 1990levels by 2020.Negative for
Arch
(ACI-$46),
Consol
(CNX-$61),
Foundation
(FCL-$54),
Peabody
(BTU-$54) and
Massey
(MEE-$57).Supports an 80% reduction in greenhouse gases(GHG) by 2050 through a cap and trademechanism. The plan also calls for the U.S. toreduce GHG emissions to 1990 levels by 2020.Negative for
Arch
,
Consol
,
Foundation
,
Peabody
and
Massey
.
Energy:
Biofuels
Opposes ethanol subsidies and wants to liftthe tariff on foreign ethanol. Negative for
Archer Daniels Midland
(ADM-$27),
Aventine
(AVR-$7),
Pacific Ethanol
(PEIX-$2), and
VeraSun
(VSE-$8).Supportive of the existing ethanol mandate.Positive for
Archer Daniels Midland,
Aventine
,
Pacific Ethanol
, and
VeraSun
.Wants 60 billion gallons of advanced biofuelslike cellulosic ethanol by 2030.
Add a Comment